Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
inFerring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study…